Mathers Edward T 4

What Happened

• Edward T. Mathers, a director of MBX Biosciences (MBX), was granted 12,500 derivative shares on June 4, 2026. The award was reported on a Form 4 filed June 5, 2026. The grant price is $0.00, so the reported acquisition value is $0. This is a compensation-related award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely).
• Transaction type: Award/other acquisition (Form 4 code A); derivative security.
• Amount and price: 12,500 shares acquired at $0.00 per share; reported value $0.
• Vesting: The grant vests in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, subject to the director’s continued service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Accession: 0001193125-26-259236 (for reference).

Context

• This appears to be a routine non-employee director compensation award (likely RSUs or a similar derivative) with a short vesting schedule; such awards are common and reflect compensation, not necessarily an insider buying or selling on personal conviction.